Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | June 09, 2026 | June 11, 2026 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director · 10% owner | January 17, 2019 | January 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
Mirati Therapeutics, Inc.
Report date January 17, 2019 · Filed January 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16 | Direct | 11,000 |
Reported balance
After 2019-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-17 · Grant · Acquired 11,000 · Balance 11,000 F1: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:15 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001579826-26-000002 · form4-06112026_040609.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001415889-25-016955 · form4-06122025_040604.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock option (right to buy) · Derivative | 25,993 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001415889-25-000880 · form4-01062025_070132.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,993 Underlying: Common Stock · 25,993 shares Expires 2035-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001415889-24-017239 · form4-06172024_050616.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 69,186 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-23-057552 · doc4.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,186 Underlying: Common Stock · 69,186 shares Expires 2033-11-30 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 25% of the shares will vest on November 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 22:01 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 21,000 | $2.35 | $49,287.00 |
DisclosureSEC source: 0001209191-23-051175 · doc4.xml · nonDerivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,024 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased at a range of prices between $2.33 and $2.38. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001209191-23-033778 · doc4.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 22:22 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 15,000 | $7.96 | $119,425.50 |
DisclosureSEC source: 0001209191-22-060738 · doc4.xml · nonDerivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,024 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased at a range of prices between $7.885 and $8.00. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:16 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001209191-22-037524 · doc4.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:17 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001209191-21-024231 · doc4.xml · nonDerivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,024 F1 · kind: The shares were purchased in the Issuer's initial public offering. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 21:54 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023463 · doc4.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-24 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $64.14 | $0.00 |
DisclosureSEC source: 0001214659-19-000460 · marketforms-43767.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 18:02 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001214659-18-000587 · marketforms-40821.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherWarrant (right to purchase) · Derivative | 78,186 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,186 shares Expires 2017-11-21 Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherWarrant (right to purchase) · Derivative | 189,780 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,780 shares Expires 2017-11-21 Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherCommon Stock | 78,186 | $7.86 | $614,541.96 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,630 F2 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Lieberburg, Reisman, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | OtherCommon Stock | 189,780 | $7.86 | $1,491,670.80 |
DisclosureSEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Reisman Neil · CIK 0001465834 · Director · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,774 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors"), (iv) Braslyn Ltd., (v) Joe Lewis, (vi) Christopher Fuglesang, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Aaron I. Davis (collectively, the "Boxer Group"). Joseph C. Lewis is the sole indirect beneficial owner of and controls Braslyn Ltd. Read SEC document |
| May 17, 2017 Filed May 19, 2017 18:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001190725-17-000129 · edgardoc.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 17:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001190725-17-000078 · primary_doc.xml · derivative · entry 1 LAPPE RODNEY W · CIK 0001579826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-03-29 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseWarrant (right to purchase) · Derivative | 51,047 | $5.60 Strike: $0.00 | $285,812.15 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,047 Underlying: Common Stock · 51,047 shares Expires not disclosed F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseWarrant (right to purchase) · Derivative | 2,341,786 | $5.60 Strike: $0.00 | $13,111,659.81 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,341,786 Underlying: Common Stock · 2,341,786 shares Expires not disclosed F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 6,104 | $5.60 | $34,182.40 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,444 F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 17:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 280,059 | $5.60 | $1,568,330.40 |
DisclosureSEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner LAPPE RODNEY W · CIK 0001579826 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Reisman Neil · CIK 0001465834 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,994 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs. F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.